GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verastem Inc (FRA:2VSA) » Definitions » Total Receivables

Verastem (FRA:2VSA) Total Receivables : €0.21 Mil (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Verastem Total Receivables?

Verastem's Total Receivables for the quarter that ended in Mar. 2024 was €0.21 Mil.


Verastem Total Receivables Historical Data

The historical data trend for Verastem's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verastem Total Receivables Chart

Verastem Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.27 0.20 0.46 0.03 -

Verastem Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.21

Verastem Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Verastem Total Receivables Related Terms

Thank you for viewing the detailed overview of Verastem's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Verastem (FRA:2VSA) Business Description

Traded in Other Exchanges
Address
117 Kendrick Street, Suite 500, Needham, MA, USA, 02494
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Verastem (FRA:2VSA) Headlines

No Headlines